You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCitalopram
Accession NumberDB00215  (APRD00147)
TypeSmall Molecule
GroupsApproved
Description

Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Citalopram and its N-demethylated metabolites exist as a racemic mixture but its effects are largely due to the S-enantiomer, S-citalopram and S-demthylcitalopram. Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Citalopram is approved for treatment of depression. Unlabeled indications include mild dementia-associated agitation in nonpsychotic patients, smoking cessation, ethanol abuse, obsessive-compulsive disorder (OCD) in children, and diabetic neuropathy. Citalopram has the fewest drug-drug interactions of the SSRIs.

Structure
Thumb
Synonyms
Citadur
Nitalapram
External Identifiers
  • Lu 10-171
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abbott-citalopramtablet40 mgoralAbbott Laboratories, Limited2014-03-122015-12-31Canada
Abbott-citalopramtablet20 mgoralAbbott Laboratories, Limited2014-03-122015-12-31Canada
Abbott-citalopramtablet10 mgoralAbbott Laboratories, Limited2014-03-172015-12-31Canada
Accel-citalopram Tabletstablet40 mgoralAccel Pharma Inc2013-07-02Not applicableCanada
Accel-citalopram Tabletstablet20 mgoralAccel Pharma Inc2013-07-02Not applicableCanada
Accel-citalopram Tabletstablet10 mgoralAccel Pharma Inc2013-03-21Not applicableCanada
Act Citalopramtablet40 mgoralActavis Pharma Company2004-01-21Not applicableCanada
Act Citalopramtablet20 mgoralActavis Pharma Company2004-01-21Not applicableCanada
Act Citalopramtablet30 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Ag-citalopramtablet20 mgoralAngita Pharma Inc.2014-09-14Not applicableCanada
Ag-citalopramtablet10 mgoralAngita Pharma Inc.2014-08-14Not applicableCanada
Ag-citalopramtablet40 mgoralAngita Pharma Inc.2014-09-14Not applicableCanada
Auro-citalopramtablet40 mgoralAuro Pharma Inc2011-11-28Not applicableCanada
Auro-citalopramtablet20 mgoralAuro Pharma Inc2011-11-28Not applicableCanada
Ava-citalopramtablet10 mgoralAvanstra Inc2011-11-232014-08-21Canada
Bio-citalopramtablet40 mgoralBiomed PharmaNot applicableNot applicableCanada
Bio-citalopramtablet20 mgoralBiomed PharmaNot applicableNot applicableCanada
Bio-citalopramtablet10 mgoralBiomed PharmaNot applicableNot applicableCanada
Celexatablet, film coated10 mg/1oralForest Laboratories, Inc.1998-07-17Not applicableUs
Celexatablet10 mg/1oralPhysicians Total Care, Inc.2004-01-30Not applicableUs
Celexatablet40 mg/1oralPhysicians Total Care, Inc.2001-09-05Not applicableUs
Celexatablet20 mg/1oralPhysicians Total Care, Inc.2000-11-28Not applicableUs
Celexatablet, film coated40 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-17Not applicableUs
Celexatablet, film coated40 mg/1oralForest Laboratories, Inc.1998-07-17Not applicableUs
Celexatablet, film coated20 mg/1oralForest Laboratories, Inc.1998-07-17Not applicableUs
Celexa 10 mgtablet10 mgoralLundbeck Canada IncNot applicableNot applicableCanada
Celexa 20 mgtablet20 mgoralLundbeck Canada Inc1999-03-08Not applicableCanada
Celexa 40 mgtablet40 mgoralLundbeck Canada Inc1999-03-08Not applicableCanada
Citalopramtablet20 mgoralSivem Pharmaceuticals Ulc2012-06-14Not applicableCanada
Citalopramtablet40 mgoralSivem Pharmaceuticals Ulc2012-06-14Not applicableCanada
Citalopramtablet40 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Citalopramtablet10 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Citalopramtablet20 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Citalopramtablet10 mgoralSivem Pharmaceuticals Ulc2012-06-14Not applicableCanada
Citalopramtablet40 mgoralMeliapharm Inc2009-02-262014-06-25Canada
Citalopramtablet20 mgoralMeliapharm Inc2009-02-262014-06-25Canada
Citalopramtablet10 mgoralMeliapharm Inc2009-02-262014-06-26Canada
Citalopramtablet10 mgoralSanis Health Inc2015-10-14Not applicableCanada
Citalopramtablet40 mgoralMylan Pharmaceuticals Ulc2009-10-222012-10-19Canada
Citalopramtablet40 mgoralSanis Health Inc2010-07-30Not applicableCanada
Citalopramtablet40 mgoralJamp Pharma Corporation2014-09-10Not applicableCanada
Citalopramtablet20 mgoralMylan Pharmaceuticals Ulc2009-10-222012-10-19Canada
Citalopramtablet20 mgoralSanis Health Inc2010-07-30Not applicableCanada
Citalopramtablet10 mgoralJamp Pharma Corporation2014-09-10Not applicableCanada
Citalopramtablet20 mgoralJamp Pharma Corporation2014-09-10Not applicableCanada
Citalopramtablet40 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Citalopramtablet20 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Citalopram Tabletstablet40 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Citalopram Tabletstablet20 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Citalopram Tablets USPtablet10 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Citalopram Tablets USPtablet40 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Citalopram Tablets USPtablet20 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Citalopram-10tablet10 mgoralPro Doc Limitee2009-06-25Not applicableCanada
Citalopram-20tablet20 mgoralPro Doc Limitee2004-12-06Not applicableCanada
Citalopram-40tablet40 mgoralPro Doc Limitee2004-12-06Not applicableCanada
Citalopram-odantablet40 mgoralOdan Laboratories Ltd2008-05-082015-11-10Canada
Citalopram-odantablet20 mgoralOdan Laboratories Ltd2008-05-082015-11-10Canada
Ctp 30tablet30 mgoralSunovion Pharmaceuticals Canada Inc2007-10-31Not applicableCanada
Dom-citalopramtablet20 mgoralDominion Pharmacal2004-02-06Not applicableCanada
Dom-citalopramtablet10 mgoralDominion Pharmacal2006-02-21Not applicableCanada
Dom-citalopramtablet40 mgoralDominion Pharmacal2004-02-06Not applicableCanada
Ecl-citalopramtablet10 mgoralEcl Pharma Group Ltd2014-10-20Not applicableCanada
Ecl-citalopramtablet20 mgoralEcl Pharma Group Ltd2014-10-20Not applicableCanada
Ecl-citalopramtablet40 mgoralEcl Pharma Group Ltd2014-10-20Not applicableCanada
Ipg-citalopramtablet20 mgoralInternational Pharmaceutical Generics Ltd2008-06-262008-11-26Canada
Ipg-citalopramtablet40 mgoralInternational Pharmaceutical Generics Ltd2008-06-262008-11-26Canada
Ipg-citalopramtablet10 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Jamp-citalopramtablet40 mgoralJamp Pharma Corporation2008-09-12Not applicableCanada
Jamp-citalopramtablet10 mgoralJamp Pharma Corporation2011-10-06Not applicableCanada
Jamp-citalopramtablet20 mgoralJamp Pharma Corporation2008-09-12Not applicableCanada
Manda-citalopramtablet10 mgoralManda Pharma Inc2012-07-032013-08-22Canada
Manda-citalopramtablet40 mgoralManda Pharma Inc2012-06-012013-08-22Canada
Manda-citalopramtablet20 mgoralManda Pharma Inc2012-06-012013-08-22Canada
Mar-citalopramtablet40 mgoralMarcan Pharmaceuticals Inc2012-09-06Not applicableCanada
Mar-citalopramtablet20 mgoralMarcan Pharmaceuticals Inc2012-09-06Not applicableCanada
Mar-citalopramtablet10 mgoralMarcan Pharmaceuticals Inc2012-09-06Not applicableCanada
Mint-citalopramtablet10 mgoralMint Pharmaceuticals Inc2011-09-13Not applicableCanada
Mint-citalopramtablet10 mgoralMint Pharmaceuticals Inc2015-10-14Not applicableCanada
Mint-citalopramtablet40 mgoralMint Pharmaceuticals Inc2008-03-10Not applicableCanada
Mint-citalopramtablet20 mgoralMint Pharmaceuticals Inc2008-03-10Not applicableCanada
Mint-citalopramtablet40 mgoralMint Pharmaceuticals Inc2015-10-14Not applicableCanada
Mint-citalopramtablet20 mgoralMint Pharmaceuticals Inc2015-10-14Not applicableCanada
Mylan-citalopramtablet40 mgoralMylan Pharmaceuticals Ulc2003-12-19Not applicableCanada
Mylan-citalopramtablet20 mgoralMylan Pharmaceuticals Ulc2003-12-19Not applicableCanada
Mylan-citalopramtablet10 mgoralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Nat-citalopramtablet40 mgoralNatco Pharma (Canada) Inc2014-02-12Not applicableCanada
Nat-citalopramtablet20 mgoralNatco Pharma (Canada) Inc2014-02-12Not applicableCanada
Nat-citalopramtablet10 mgoralNatco Pharma (Canada) Inc2014-02-12Not applicableCanada
Nat-citalopram Tabletstablet40 mgoralNatco Pharma (Canada) IncNot applicableNot applicableCanada
Nat-citalopram Tabletstablet20 mgoralNatco Pharma (Canada) IncNot applicableNot applicableCanada
Ng Citalopramtablet40 mgoralNext Generation Pharma Inc2009-08-142011-08-30Canada
Ng Citalopramtablet20 mgoralNext Generation Pharma Inc2009-08-142011-08-30Canada
Novo-citalopramtablet40 mgoralNovopharm Limited2004-08-272011-11-08Canada
Novo-citalopramtablet20 mgoralNovopharm Limited2004-08-272011-11-08Canada
Ntp-citalopramtablet40 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-citalopramtablet20 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-citalopramtablet10 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Nu-citalopramtablet40 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-citalopramtablet20 mgoralNu Pharm IncNot applicableNot applicableCanada
Pendo-citalopramtablet20 mgoralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
PHL-citalopramtablet10 mgoralPharmel Inc2006-03-13Not applicableCanada
PHL-citalopramtablet40 mgoralPharmel Inc2004-04-06Not applicableCanada
PHL-citalopramtablet20 mgoralPharmel Inc2004-04-06Not applicableCanada
PMS-citalopramtablet10 mgoralPharmascience Inc2005-09-10Not applicableCanada
PMS-citalopramtablet40 mgoralPharmascience Inc2004-01-15Not applicableCanada
PMS-citalopramtablet20 mgoralPharmascience Inc2004-01-15Not applicableCanada
Priva-citalopramtablet40 mgoralPharmapar IncNot applicableNot applicableCanada
Priva-citalopramtablet20 mgoralPharmapar IncNot applicableNot applicableCanada
Priva-citalopramtablet10 mgoralPharmapar IncNot applicableNot applicableCanada
Q-citalopramtablet40 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-citalopramtablet10 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-citalopramtablet20 mgoralQd Pharmaceuticals Ulc2011-11-242015-08-21Canada
Ran-citalotablet40 mgoralRanbaxy Pharmaceuticals Canada Inc.2006-12-07Not applicableCanada
Ran-citalotablet20 mgoralRanbaxy Pharmaceuticals Canada Inc.2006-12-07Not applicableCanada
Ran-citalopramtablet40 mgoralRanbaxy Pharmaceuticals Canada Inc.2005-07-142010-08-06Canada
Ran-citalopramtablet20 mgoralRanbaxy Pharmaceuticals Canada Inc.2005-07-142010-08-06Canada
Ratio-citalopramtablet40 mgoralTeva Canada Limited2004-04-262012-12-21Canada
Ratio-citalopramtablet20 mgoralTeva Canada Limited2004-04-262012-12-21Canada
Riva-citalopramtablet20 mgoralLaboratoire Riva Inc2008-01-28Not applicableCanada
Riva-citalopramtablet10 mgoralLaboratoire Riva Inc2008-01-24Not applicableCanada
Riva-citalopramtablet40 mgoralLaboratoire Riva Inc2004-03-242013-07-31Canada
Riva-citalopramtablet20 mgoralLaboratoire Riva Inc2004-03-242014-07-29Canada
Riva-citalopramtablet40 mgoralLaboratoire Riva Inc2008-01-28Not applicableCanada
Riva-citalopramtablet10 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Sandoz Citalopramtablet40 mgoralSandoz Canada Incorporated2004-01-30Not applicableCanada
Sandoz Citalopramtablet20 mgoralSandoz Canada Incorporated2004-01-30Not applicableCanada
Septa-citalopramtablet10 mgoralSepta Pharmaceuticals Inc2015-09-18Not applicableCanada
Septa-citalopramtablet40 mgoralSepta Pharmaceuticals Inc2010-10-15Not applicableCanada
Septa-citalopramtablet20 mgoralSepta Pharmaceuticals Inc2010-10-15Not applicableCanada
Teva-citalopramtablet40 mgoralTeva Canada Limited2007-12-03Not applicableCanada
Teva-citalopramtablet20 mgoralTeva Canada Limited2007-09-19Not applicableCanada
Teva-citalopramtablet10 mgoralTeva Canada Limited2008-12-15Not applicableCanada
Van-citalopramtablet40 mgoralVanc Pharmaceuticals Inc2016-02-01Not applicableCanada
Van-citalopramtablet20 mgoralVanc Pharmaceuticals Inc2016-02-01Not applicableCanada
Van-citalopramtablet10 mgoralVanc Pharmaceuticals Inc2016-02-01Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-citalopramtablet40 mgoralApotex Inc2004-01-21Not applicableCanada
Apo-citalopramtablet20 mgoralApotex Inc2004-01-21Not applicableCanada
Citalopramsolution10 mg/5mLoralRoxane Laboratories, Inc2004-05-25Not applicableUs
Citalopramtablet20 mg/1oralBlu Pharmaceuticals, LLC2007-04-03Not applicableUs
Citalopramtablet, film coated20 mg/1oralSafecor Health, LLC2014-09-30Not applicableUs
Citalopramtablet, film coated10 mg/1oralEpic Pharma, LLC2011-05-20Not applicableUs
Citalopramtablet10 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-22Not applicableUs
Citalopramtablet, film coated40 mg/1oralBlenheim Pharmacal, Inc.2011-05-20Not applicableUs
Citalopramtablet40 mg/1oralG&W Laboratories, Inc.2015-12-02Not applicableUs
Citalopramtablet20 mg/1oralCardinal Health2011-01-19Not applicableUs
Citalopramtablet, film coated20 mg/1oralJubilant Cadista Pharmaceuticals Inc.2015-12-23Not applicableUs
Citalopramtablet20 mg/1oralDIRECT RX2015-01-01Not applicableUs
Citalopramtablet, film coated20 mg/1oralAurobindo Pharma Limited2004-10-28Not applicableUs
Citalopramtablet10 mg/1oralTeva Pharmaceuticals USA Inc2007-02-222015-11-30Us
Citalopramtablet20 mg/1oralREMEDYREPACK INC.2013-02-25Not applicableUs
Citalopramtablet40 mg/1oralMed Vantx, Inc.2012-04-24Not applicableUs
Citalopramtablet, film coated20 mg/1oralProficient Rx LP2004-10-28Not applicableUs
Citalopramtablet40 mg/1oralAphena Pharma Solutions New Jersey, Llc2010-09-13Not applicableUs
Citalopramtablet20 mg/1oralAmerican Health Packaging2013-07-252015-12-31Us
Citalopramtablet, film coated10 mg/1oralInternational Laboratories, Inc.2008-06-25Not applicableUs
Citalopramtablet40 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Citalopramtablet20 mg/1oralG&W Laboratories, Inc.2015-12-02Not applicableUs
Citalopramtablet, film coated40 mg/1oralMylan Pharmaceuticals Inc.2008-07-28Not applicableUs
Citalopramtablet, film coated20 mg/1oralBlenheim Pharmacal, Inc.2013-09-30Not applicableUs
Citalopramtablet10 mg/1oralCardinal Health2011-01-19Not applicableUs
Citalopramtablet, film coated40 mg/1oralApotex Corp.2011-08-01Not applicableUs
Citalopramtablet, film coated10 mg/1oralJubilant Cadista Pharmaceuticals Inc.2015-12-23Not applicableUs
Citalopramtablet, film coated10 mg/1oralAurobindo Pharma Limited2004-10-28Not applicableUs
Citalopramtablet, film coated20 mg/1oralContract Pharmacy Services Pa2010-04-06Not applicableUs
Citalopramtablet40 mg/1oralREMEDYREPACK INC.2013-03-04Not applicableUs
Citalopramtablet, film coated10 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Citalopramtablet, film coated10 mg/1oralDIRECT RX2016-03-22Not applicableUs
Citalopramtablet20 mg/1oralAphena Pharma Solutions New Jersey, Llc2010-09-13Not applicableUs
Citalopramtablet, film coated20 mg/1oralInternational Laboratories, Inc.2008-06-25Not applicableUs
Citalopramtablet10 mg/1oralG&W Laboratories, Inc.2015-12-02Not applicableUs
Citalopramtablet, film coated20 mg/1oralMylan Pharmaceuticals Inc.2008-07-28Not applicableUs
Citalopramtablet10 mg/1oralBlu Pharmaceuticals, LLC2007-04-03Not applicableUs
Citalopramtablet40 mg/1oralBlenheim Pharmacal, Inc.2010-01-04Not applicableUs
Citalopramtablet, film coated20 mg/1oralApotex Corp.2011-08-01Not applicableUs
Citalopramtablet40 mg/1oralNew Horizon Rx Group, LLC2013-08-25Not applicableUs
Citalopramtablet, film coated20 mg/1oralREMEDYREPACK INC.2015-12-24Not applicableUs
Citalopramtablet40 mg/1oralAmneal Pharmaceuticals of New York, LLC2010-04-06Not applicableUs
Citalopramtablet, film coated20 mg/1oralAmerican Health Packaging2014-04-01Not applicableUs
Citalopramtablet, film coated40 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Citalopramtablet, film coated20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2004-10-28Not applicableUs
Citalopramtablet10 mg/1oralAphena Pharma Solutions New Jersey, Llc2010-09-13Not applicableUs
Citalopramtablet, film coated10 mg/1oralMylan Pharmaceuticals Inc.2008-07-28Not applicableUs
Citalopramtablet40 mg/1oralPd Rx Pharmaceuticals, Inc.2010-09-13Not applicableUs
Citalopramtablet, film coated10 mg/1oralApotex Corp.2011-08-01Not applicableUs
Citalopramtablet40 mg/1oralClinical Solutions Wholesale2007-11-08Not applicableUs
Citalopramtablet20 mg/1oralAmneal Pharmaceuticals of New York, LLC2010-04-06Not applicableUs
Citalopramtablet, film coated10 mg/1oralAmerican Health Packaging2014-04-01Not applicableUs
Citalopramtablet40 mg/1oralUnit Dose Services2009-01-01Not applicableUs
Citalopramtablet40 mg/1oralPreferred Pharmaceuticals, Inc.2014-10-17Not applicableUs
Citalopramtablet, film coated40 mg/1oralLake Erie Medical DBA Quality Care Products LLC2004-10-28Not applicableUs
Citalopramtablet20 mg/1oralH.J. Harkins Company, Inc.2009-01-01Not applicableUs
Citalopramtablet20 mg/1oralInternational Labs, Inc.2013-08-01Not applicableUs
Citalopramtablet, film coated40 mg/1oralEon Labs, Inc.2004-10-28Not applicableUs
Citalopramtablet20 mg/1oralBlenheim Pharmacal, Inc.2010-01-04Not applicableUs
Citalopramtablet10 mg/1oralAmneal Pharmaceuticals of New York, LLC2010-04-06Not applicableUs
Citalopramtablet, film coated10 mg/1oralRed Pharm Drug Inc.2004-10-28Not applicableUs
Citalopramtablet40 mg/1oralContract Pharmacy Services Pa2010-06-30Not applicableUs
Citalopramtablet40 mg/1oralMc Kesson Contract Packaging2011-09-22Not applicableUs
Citalopramtablet20 mg/1oralPreferred Pharmaceuticals, Inc2011-02-09Not applicableUs
Citalopramtablet, film coated20 mg/1oralREMEDYREPACK INC.2014-05-28Not applicableUs
Citalopramtablet, film coated10 mg/1oralPhysicians Total Care, Inc.2010-01-14Not applicableUs
Citalopramtablet, film coated40 mg/1oralInternational Laboratories, Inc.2014-01-01Not applicableUs
Citalopramtablet, film coated20 mg/1oralEon Labs, Inc.2004-10-28Not applicableUs
Citalopramtablet40 mg/1oralCamber Pharmaceuticals2011-01-01Not applicableUs
Citalopramtablet, film coated40 mg/1oralRebel Distributors Corp.2007-03-27Not applicableUs
Citalopramtablet40 mg/1oralRebel Distributors Corp2011-01-01Not applicableUs
Citalopramtablet40 mg/1oralAurolife Pharma LLC2009-01-01Not applicableUs
Citalopramtablet20 mg/1oralBlenheim Pharmacal, Inc.2010-07-06Not applicableUs
Citalopramtablet, film coated10 mg/1oralCardinal Health2013-02-08Not applicableUs
Citalopramtablet40 mg/1oralGolden State Medical Supply, Inc.2011-05-20Not applicableUs
Citalopramtablet20 mg/1oralClinical Solutions Wholesale2009-01-01Not applicableUs
Citalopramtablet, film coated40 mg/1oralProficient Rx LP2004-10-28Not applicableUs
Citalopramtablet, film coated10 mg/1oralREMEDYREPACK INC.2015-07-22Not applicableUs
Citalopramtablet20 mg/1oralMc Kesson Contract Packaging2011-09-01Not applicableUs
Citalopramtablet20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-11-22Not applicableUs
Citalopramtablet40 mg/1oralLegacy Pharmaceutical Packaging, Llc2011-01-01Not applicableUs
Citalopramtablet, film coated40 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Citalopramtablet, film coated20 mg/1oralPhysicians Total Care, Inc.2008-01-18Not applicableUs
Citalopramtablet40 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Citalopramtablet40 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-11-08Not applicableUs
Citalopramtablet, film coated10 mg/1oralEon Labs, Inc.2004-10-28Not applicableUs
Citalopramtablet20 mg/1oralCamber Pharmaceuticals2011-01-01Not applicableUs
Citalopramtablet, film coated20 mg/1oralRebel Distributors Corp.2007-03-27Not applicableUs
Citalopramtablet20 mg/1oralPd Rx Pharmaceuticals, Inc.2010-09-13Not applicableUs
Citalopramtablet10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2009-01-01Not applicableUs
Citalopramtablet20 mg/1oralAurolife Pharma LLC2009-01-01Not applicableUs
Citalopramtablet, film coated40 mg/1oralCardinal Health2013-02-08Not applicableUs
Citalopramtablet20 mg/1oralGolden State Medical Supply, Inc.2011-05-20Not applicableUs
Citalopramtablet, film coated40 mg/1oralREMEDYREPACK INC.2015-05-15Not applicableUs
Citalopramtablet20 mg/1oralMed Vantx, Inc.2007-02-22Not applicableUs
Citalopramtablet20 mg/1oralContract Pharmacy Services Pa2010-06-30Not applicableUs
Citalopramtablet, film coated40 mg/1oralPhysicians Total Care, Inc.2007-01-22Not applicableUs
Citalopramtablet20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-02-22Not applicableUs
Citalopramtablet40 mg/1oralTeva Pharmaceuticals USA Inc2007-11-082016-03-31Us
Citalopramtablet10 mg/1oralCamber Pharmaceuticals2011-01-01Not applicableUs
Citalopramtablet, film coated10 mg/1oralRebel Distributors Corp.2007-03-27Not applicableUs
Citalopramtablet, film coated40 mg/1oralEpic Pharma, LLC2011-05-20Not applicableUs
Citalopramtablet20 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-01-01Not applicableUs
Citalopramtablet10 mg/1oralAurolife Pharma LLC2009-01-01Not applicableUs
Citalopramtablet, film coated20 mg/1oralCardinal Health2013-02-08Not applicableUs
Citalopramtablet10 mg/1oralGolden State Medical Supply, Inc.2011-05-20Not applicableUs
Citalopramtablet40 mg/1oralREMEDYREPACK INC.2014-12-15Not applicableUs
Citalopramtablet, film coated40 mg/1oralContract Pharmacy Services Pa2010-04-07Not applicableUs
Citalopramtablet10 mg/1oralContract Pharmacy Services Pa2010-06-30Not applicableUs
Citalopramtablet10 mg/1oralMc Kesson Contract Packaging2011-09-22Not applicableUs
Citalopramtablet40 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-11-22Not applicableUs
Citalopramtablet, film coated20 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Citalopramtablet20 mg/1oralREMEDYREPACK INC.2013-05-08Not applicableUs
Citalopramtablet10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-02-22Not applicableUs
Citalopramtablet20 mg/1oralTeva Pharmaceuticals USA Inc2007-02-222016-02-29Us
Citalopramtablet40 mg/1oralBlu Pharmaceuticals, LLC2007-04-03Not applicableUs
Citalopramtablet, film coated20 mg/1oralEpic Pharma, LLC2011-05-20Not applicableUs
Citalopramtablet40 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-01-01Not applicableUs
Citalopramtablet40 mg/1oralCardinal Health2011-01-19Not applicableUs
Citalopramtablet, film coated40 mg/1oralJubilant Cadista Pharmaceuticals Inc.2015-12-23Not applicableUs
Citalopramtablet40 mg/1oralClinical Solutions Wholesale, Llc2011-01-01Not applicableUs
Citalopramtablet40 mg/1oralSt Marys Medical Park Pharmacy2014-05-23Not applicableUs
Citalopramtablet, film coated40 mg/1oralAurobindo Pharma Limited2004-10-28Not applicableUs
Citalopramtablet20 mg/1oralReady Meds2011-01-01Not applicableUs
Citalopramtablet40 mg/1oralMed Vantx, Inc.2007-11-08Not applicableUs
Citalopramtablet, film coated10 mg/1oralAvera Mc Kennan Hospital2015-03-04Not applicableUs
Citalopramtablet40 mg/1oralREMEDYREPACK INC.2013-03-04Not applicableUs
Citalopramtablet40 mg/1oralLegacy Pharmaceutical Packaging2010-04-30Not applicableUs
Citalopramtablet10 mg/1oralAmerican Health Packaging2013-07-252015-12-29Us
Citalopramtablet, film coated40 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralAidarex Pharmaceuticals LLC2007-10-18Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralStat Rx USA2007-10-18Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralStat Rx USA2007-10-18Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralSun Pharmaceutical Industries, Inc.2015-05-29Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralSt Marys Medical Park Pharmacy2007-10-18Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralCardinal Health2009-11-02Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralbryant ranch prepack2004-11-12Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralClinical Solutions Wholesale, Llc2007-10-18Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralMed Vantx, Inc.2007-10-18Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralSt Marys Medical Park Pharmacy2014-01-23Not applicableUs
Citalopram Hydrobromidetablet, film coated20 mg/1oralGlenmark Generics Inc., USA2009-02-27Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralbryant ranch prepack2004-11-12Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralContract Pharmacy Services Pa2010-07-01Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralPreferred Pharmaceuticals, Inc.2013-03-26Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralREMEDYREPACK INC.2011-05-16Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Citalopram Hydrobromidetablet, film coated40 mg/1oralGlenmark Generics Inc., USA2009-02-27Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralREMEDYREPACK INC.2011-04-20Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralCardinal Health2009-11-02Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralREMEDYREPACK INC.2013-03-18Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralRebel Distributors Corp2007-10-18Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralTorrent Pharmaceuticals Limited2007-10-18Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralSun Pharmaceutical Industries, Inc.2015-05-29Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralbryant ranch prepack2004-11-12Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralDIRECT RX2014-01-01Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralMed Vantx, Inc.2007-10-18Not applicableUs
Citalopram Hydrobromidetablet, film coated10 mg/1oralGlenmark Generics Inc., USA2009-02-27Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralExelan Pharmaceuticals Inc.2012-10-01Not applicableUs
Citalopram Hydrobromidetablet40 mg/301oralNorthwind Pharmaceuticals2014-04-03Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralPreferred Pharmaceuticals Inc.2016-01-04Not applicableUs
Citalopram Hydrobromidetablet, film coated40 mg/1oralDr. Reddy's Laboratories Limited2004-10-28Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralAidarex Pharmaceuticals LLC2007-10-18Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralPd Rx Pharmaceuticals, Inc.2007-10-18Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralTorrent Pharmaceuticals Limited2007-10-18Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralSun Pharmaceutical Industries, Inc.2015-05-29Not applicableUs
Citalopram Hydrobromidetablet, film coated40 mg/1oralCardinal Health2004-11-24Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralProficient Rx LP2007-10-18Not applicableUs
Citalopram Hydrobromidetablet, film coated40 mg/1oralMed Vantx, Inc.2004-10-28Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralExelan Pharmaceuticals Inc.2012-10-01Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralNorthwind Pharmaceuticals, LLC2015-02-16Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralPreferred Pharmaceuticals, Inc.2013-03-26Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralREMEDYREPACK INC.2011-08-08Not applicableUs
Citalopram Hydrobromidetablet, film coated20 mg/1oralDr. Reddy's Laboratories Limited2004-10-28Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralInternational Labs, Inc.2012-02-20Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-10-18Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralAidarex Pharmaceuticals LLC2007-10-18Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralREMEDYREPACK INC.2014-12-29Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralRebel Distributors Corp2007-10-18Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralProficient Rx LP2007-10-18Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralREMEDYREPACK INC.2015-07-27Not applicableUs
Citalopram Hydrobromidetablet, film coated40 mg/1oralMed Vantx, Inc.2004-10-28Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralContract Pharmacy Services Pa2010-07-01Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralExelan Pharmaceuticals Inc.2012-10-01Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralREMEDYREPACK INC.2011-07-28Not applicableUs
Citalopram Hydrobromidetablet, film coated20 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Citalopram Hydrobromidetablet, film coated10 mg/1oralDr. Reddy's Laboratories Limited2004-10-28Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-10-18Not applicableUs
Citalopram Hydrobromidesolution10 mg/5mLoralCamber Pharmaceuticals, Inc.2015-12-21Not applicableUs
Citalopram Hydrobromidetablet, film coated40 mg/1oralREMEDYREPACK INC.2010-12-16Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralPd Rx Pharmaceuticals, Inc.2004-11-12Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralRebel Distributors Corp2007-10-18Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralTorrent Pharmaceuticals Limited2007-10-18Not applicableUs
Citalopram Hydrobromidesolution10 mg/5mLoralCitron Pharma LLC2006-08-28Not applicableUs
Citalopram Hydrobromidetablet, film coated20 mg/1oralCardinal Health2004-11-24Not applicableUs
Citalopram Hydrobromidetablet, film coated20 mg/1oralMed Vantx, Inc.2004-10-28Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralUnit Dose Services2007-10-18Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralREMEDYREPACK INC.2011-07-25Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralREMEDYREPACK INC.2016-02-10Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-10-18Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralPd Rx Pharmaceuticals, Inc.2004-11-12Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralLake Erie Medical DBA Quality Care Products LLC2004-11-12Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralREMEDYREPACK INC.2011-07-22Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralREMEDYREPACK INC.2014-02-20Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralMajor Pharmaceuticals2009-11-02Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2004-11-12Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralClinical Solutions Wholesale2004-11-12Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralDIRECT RX2014-01-01Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralTYA Pharmaceuticals2004-11-12Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralContract Pharmacy Services Pa2009-09-01Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralMajor Pharmaceuticals2009-11-02Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralPd Rx Pharmaceuticals, Inc.2004-11-12Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralClinical Solutions Wholesale2004-11-12Not applicableUs
Citalopram Hydrobromidesolution10 mg/5mLoralAurobindo Pharma Limited2006-08-28Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralTYA Pharmaceuticals2007-10-18Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralLegacy Pharmaceutical Packaging2010-10-01Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralREMEDYREPACK INC.2011-06-08Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralStat Rx USA2007-10-18Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralBlenheim Pharmacal, Inc.2013-10-04Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralMajor Pharmaceuticals2009-11-02Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralCardinal Health2009-11-02Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralContract Pharmacy Services Pa2010-07-01Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralREMEDYREPACK INC.2011-04-26Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralREMEDYREPACK INC.2013-05-06Not applicableUs
Citalopram Hydrobromidesolution10 mg/5mLoralSilarx Pharmaceuticals, Inc2006-06-14Not applicableUs
Direct Rxtablet40 mg/1oralDIRECT RX2015-01-01Not applicableUs
Direct Rxtablet20 mg/1oralDIRECT RX2015-01-01Not applicableUs
Perrigo Citalopramtablet20 mg/1oralContract Pharmacy Services Pa2010-02-25Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AkarinNot Available
CelapramNot Available
CiazilNot Available
CiliftNot Available
CipramNot Available
CipramilNot Available
CiprapineNot Available
CitabaxNot Available
CitalecNot Available
CitolNot Available
CitopamNot Available
CitoxNot Available
CitrolNot Available
DalsanNot Available
ElopramNot Available
HumorupNot Available
OropramNot Available
PramcitNot Available
RecitalNot Available
SeropramNot Available
TalamNot Available
TalohexalNot Available
TemperaxNot Available
VodelaxNot Available
ZentiusNot Available
ZetaloNot Available
Brand mixtures
NameLabellerIngredients
Sentralopram Am-10Physician Therapeutics Llc
Salts
Name/CASStructureProperties
Citalopram Hydrobromide
59729-32-7
Thumb
  • InChI Key: WIHMBLDNRMIGDW-UHFFFAOYNA-N
  • Monoisotopic Mass: 404.089954188
  • Average Mass: 405.304
DBSALT000027
Categories
UNII0DHU5B8D6V
CAS number59729-33-8
WeightAverage: 324.3919
Monoisotopic: 324.163791509
Chemical FormulaC20H21FN2O
InChI KeyInChIKey=WSEQXVZVJXJVFP-UHFFFAOYSA-N
InChI
InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
IUPAC Name
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
SMILES
CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylbutylamines. These are compounds containing a phenylbutylamine moiety, which consists of a phenyl group substituted at the fourth carbon by an butan-1-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylbutylamines
Direct ParentPhenylbutylamines
Alternative Parents
Substituents
  • Phenylbutylamine
  • Benzonitrile
  • Aralkylamine
  • Halobenzene
  • Fluorobenzene
  • Aryl halide
  • Aryl fluoride
  • Tertiary aliphatic amine
  • Tertiary amine
  • Oxacycle
  • Organoheterocyclic compound
  • Nitrile
  • Carbonitrile
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of depression. Unlabeled indications include: treatment of mild dementia-associated agitation in nonpsychotic patients, smoking cessation, ethanol abuse, obsessive-compulsive disorder (OCD) in children, and diabetic neuropathy.
PharmacodynamicsCitalopram is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). It is used to treat the depression associated with mood disorders. It is also used on occassion in the treatment of body dysmorphic disorder and anxiety. The antidepressant, antiobsessive-compulsive, and antibulimic actions of citalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. In vitro studies show that citalopram is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake. Citalopram has no significant affinity for adrenergic (α1, α2, β), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. The chronic administration of citalopram was found to downregulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major depressive disorder. Citalopram does not inhibit monoamine oxidase.
Mechanism of actionThe antidepressant, antiobsessive-compulsive, and antibulimic actions of citalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. Citalopram blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT1A autoreceptors. SSRIs bind with significantly less affinity to histamine, acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs.
Related Articles
AbsorptionRapidly and well absorbed from the GI tract. Peak plasma concentrations occur within 4 hours of a single orally administered dose. Bioavailability is 80% following oral administration. Food does not affect absorption.
Volume of distribution
  • 12 L/kg
    Citalopram is highly lipophilic and likely widely distributed throughout the body, including the blood-brain-barrier. However, its metabolite, demethylcitalopram does not cross the barrier well.
Protein bindingCitalopram, dimethylcitalopram, and didemethylcitalopram is 80% bound to plasma proteins.
Metabolism

Citalopram is metabolized mainly in the liver via N-demethylation to its principle metabolite, demethylcitalopram. Other metabolites include didemethylcitalopram, citalopram N-oxide, and a deaminated propionic acid derivative. However, the predominant entity in plasma is unchanged citalopram. Cytochrome P450 (CYP) 3A4 and 2C19 isozymes appear to be principally involved in producing demethylcitalopram. Demethylcitalopram appears to be further N-demethylated by CYP2D6 to didemethylcitalopram. Citalopram metabolites possess little pharmacologic activity in comparison to their parent compound and do not likely contribute to the clinical effect of the drug.

SubstrateEnzymesProduct
Citalopram
Citalopram N-oxideDetails
Citalopram
N-DesmethylcitalopramDetails
Citalopram
Not Available
Citalopram propionic acidDetails
N-Desmethylcitalopram
N,N-DidesmethylcitalopramDetails
Route of elimination12-23% of an oral dose of citalopram is recovered unchanged in the urine, while 10% of the dose is recovered in the feces.
Half life35 hours
Clearance

The systemic clearance of citalopram was 330 mL/min, with approximately 20% of that due to renal clearance.

ToxicitySymptoms most often accompanying citalopram overdose, alone or in combination with other drugs and/or alcohol, included dizziness, sweating, nausea, vomiting, tremor, somnolence, and sinus tachycardia. In more rare cases, observed symptoms included amnesia, confusion, coma, convulsions, hyperventilation, cyanosis, rhabdomyolysis, and ECG changes (including QTc prolongation, nodal rhythm, ventricular arrhythmia, and very rare cases of torsade de pointes). Acute renal failure has been very rarely reported accompanying overdose. Withdrawal symptoms include flu-like symptoms, insomnia, nausea, imbalance, sensory changes and hyperactivity.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Citalopram Action PathwayDrug actionSMP00424
Citalopram Metabolism PathwayDrug metabolismSMP00627
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Multidrug resistance protein 1
Gene symbol: ABCB1
UniProt: P08183
rs2032583 Not AvailableC AlleleImproved response to antidepressant medication17913323
5-hydroxytryptamine receptor 2A
Gene symbol: HTR2A
UniProt: P28223
rs7997012 Not AvailableA AlleleImproved response to antidepressant medication16642436
Glutamate receptor ionotropic, kainate 4
Gene symbol: GRIK4
UniProt: Q16099
rs1954787 Not AvailableC AlleleImproved response to antidepressant medication17671280
5-hydroxytryptamine receptor 1A
Gene symbol: HTR1A
UniProt: P08908
rs6295 Not AvailableG AlleleHomozygosity for the rs6295 G allele is associated with lower response rate in patients treated for major depression19829169
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Glutamate receptor ionotropic, kainate 2
Gene symbol: GRIK2
UniProt: Q13002
rs2518224 Not AvailableC Allele, homozygoteIncreased suicidal thoughts17898344
Glutamate receptor 3
Gene symbol: GRIA3
UniProt: P42263
rs4825476 Not AvailableG Allele, homozygoteIncreased suicidal thoughts17898344
Cyclic AMP-responsive element-binding protein 1
Gene symbol: CREB1
UniProt: P16220
rs4675690 Not AvailableT AlleleElevated suicide risk17548750
Cyclic AMP-responsive element-binding protein 1
Gene symbol: CREB1
UniProt: P16220
rs7569963 Not AvailableA AlleleElevated suicide risk17548750
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9966
Blood Brain Barrier+0.9729
Caco-2 permeable+0.6099
P-glycoprotein substrateSubstrate0.7597
P-glycoprotein inhibitor INon-inhibitor0.6361
P-glycoprotein inhibitor IIInhibitor0.9789
Renal organic cation transporterInhibitor0.6993
CYP450 2C9 substrateNon-substrate0.8401
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.5054
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5223
Ames testNon AMES toxic0.7602
CarcinogenicityNon-carcinogens0.7452
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9054 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7735
hERG inhibition (predictor II)Inhibitor0.8994
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Alphapharm party ltd
  • Forest laboratories inc
  • Apotex inc richmond hill
  • Aurobindo pharma ltd inc
  • Roxane laboratories inc
  • Silarx pharmaceuticals inc
  • Biovail laboratories international srl
  • Actavis elizabeth llc
  • Amneal pharmaceuticals ny llc
  • Apotex inc etobicoke site
  • Aurobindo pharma ltd
  • Caraco pharmaceutical laboratories ltd
  • Corepharma llc
  • Dr reddys laboratories ltd
  • Epic pharma llc
  • Glenmark generics ltd
  • Invagen pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Matrix laboratories inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Natco pharma ltd
  • Pliva inc
  • Sandoz inc
  • Taro pharmaceuticals usa inc
  • Teva pharmaceuticals usa
  • Torrent pharmaceuticals ltd
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral20 mg
Tabletoral40 mg
Solutionoral10 mg/5mL
Tabletoral10 mg/1
Tabletoral20 mg/1
Tabletoral40 mg/1
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral20 mg/1
Tablet, film coatedoral40 mg/1
Tabletoral40 mg/301
Tabletoral30 mg
Tabletoral10 mg
Kit
Prices
Unit descriptionCostUnit
Citalopram Hydrobromide 10 mg/5ml Solution 240ml Bottle122.28USD bottle
Celexa 40 mg tablet3.88USD tablet
Celexa 20 mg tablet3.72USD tablet
Celexa 10 mg tablet3.57USD tablet
Citalopram Hydrobromide 40 mg tablet2.89USD tablet
Citalopram Hydrobromide 20 mg tablet2.8USD tablet
Citalopram Hydrobromide 10 mg tablet2.68USD tablet
Citalopram hbr 40 mg tablet2.53USD tablet
Citalopram hbr 20 mg tablet2.43USD tablet
Citalopram hbr 10 mg tablet2.33USD tablet
Celexa 20 mg Tablet1.47USD tablet
Celexa 40 mg Tablet1.47USD tablet
Ctp 30 30 mg Tablet0.99USD tablet
Apo-Citalopram 20 mg Tablet0.82USD tablet
Apo-Citalopram 40 mg Tablet0.82USD tablet
Citalopram 20 mg Tablet0.82USD tablet
Citalopram 40 mg Tablet0.82USD tablet
Citalopram-Odan 20 mg Tablet0.82USD tablet
Citalopram-Odan 40 mg Tablet0.82USD tablet
Co Citalopram 20 mg Tablet0.82USD tablet
Co Citalopram 40 mg Tablet0.82USD tablet
Jamp-Citalopram 20 mg Tablet0.82USD tablet
Jamp-Citalopram 40 mg Tablet0.82USD tablet
Mint-Citalopram 20 mg Tablet0.82USD tablet
Mint-Citalopram 40 mg Tablet0.82USD tablet
Mylan-Citalopram 20 mg Tablet0.82USD tablet
Mylan-Citalopram 40 mg Tablet0.82USD tablet
Ng Citalopram 20 mg Tablet0.82USD tablet
Ng Citalopram 40 mg Tablet0.82USD tablet
Novo-Citalopram 20 mg Tablet0.82USD tablet
Novo-Citalopram 40 mg Tablet0.82USD tablet
Phl-Citalopram 20 mg Tablet0.82USD tablet
Phl-Citalopram 40 mg Tablet0.82USD tablet
Pms-Citalopram 20 mg Tablet0.82USD tablet
Pms-Citalopram 40 mg Tablet0.82USD tablet
Ran-Citalo 20 mg Tablet0.82USD tablet
Ran-Citalo 40 mg Tablet0.82USD tablet
Ran-Citalopram 20 mg Tablet0.82USD tablet
Ran-Citalopram 40 mg Tablet0.82USD tablet
Ratio-Citalopram 20 mg Tablet0.82USD tablet
Ratio-Citalopram 40 mg Tablet0.82USD tablet
Sandoz Citalopram 20 mg Tablet0.82USD tablet
Sandoz Citalopram 40 mg Tablet0.82USD tablet
Pms-Citalopram 10 mg Tablet0.47USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2049368 No2001-10-232011-08-16Canada
CA2353693 No2003-07-222021-07-24Canada
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point182-183 °CNot Available
water solubilitySparingly soluble FDA label
logP3.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00588 mg/mLALOGPS
logP3.58ALOGPS
logP3.76ChemAxon
logS-4.7ALOGPS
pKa (Strongest Basic)9.78ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area36.26 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity94.02 m3·mol-1ChemAxon
Polarizability35.4 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
MSMass Spectrum (Electron Ionization)splash10-0a4i-9110000000-5b1fde1b7a58929c7f2dView in MoNA
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
References
Synthesis Reference

Hans Petersen, “Method for the preparation of citalopram.” U.S. Patent US6229026, issued December, 1992.

US6229026
General References
  1. Sindrup SH, Bjerre U, Dejgaard A, Brosen K, Aaes-Jorgensen T, Gram LF: The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther. 1992 Nov;52(5):547-52. [PubMed:1424428 ]
  2. Atmaca M, Kuloglu M, Tezcan E, Semercioz A: The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. Int J Impot Res. 2002 Dec;14(6):502-5. [PubMed:12494286 ]
  3. Andersen G, Vestergaard K, Riis JO: Citalopram for post-stroke pathological crying. Lancet. 1993 Oct 2;342(8875):837-9. [PubMed:8104273 ]
  4. Clayton A, Keller A, McGarvey EL: Burden of phase-specific sexual dysfunction with SSRIs. J Affect Disord. 2006 Mar;91(1):27-32. Epub 2006 Jan 20. [PubMed:16430968 ]
  5. Baumann P: Pharmacology and pharmacokinetics of citalopram and other SSRIs. Int Clin Psychopharmacol. 1996 Mar;11 Suppl 1:5-11. [PubMed:8732438 ]
  6. Hyttel J, Bogeso KP, Perregaard J, Sanchez C: The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm Gen Sect. 1992;88(2):157-60. [PubMed:1632943 ]
  7. Caccia S: Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet. 1998 Apr;34(4):281-302. [PubMed:9571301 ]
External Links
ATC CodesN06AB04
AHFS Codes
  • 28:16.04.20
PDB EntriesNot Available
FDA labelDownload (148 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabCitalopram may increase the anticoagulant activities of Abciximab.
AbirateroneThe serum concentration of Citalopram can be increased when it is combined with Abiraterone.
AcenocoumarolCitalopram may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Acepromazine.
AcetophenazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Acetophenazine.
Acetylsalicylic acidCitalopram may increase the antiplatelet activities of Acetylsalicylic acid.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Citalopram.
AlteplaseCitalopram may increase the anticoagulant activities of Alteplase.
AmantadineAmantadine may increase the QTc-prolonging activities of Citalopram.
AmiodaroneCitalopram may increase the QTc-prolonging activities of Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Citalopram is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Citalopram.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Citalopram.
AnagrelideCitalopram may increase the QTc-prolonging activities of Anagrelide.
AnistreplaseCitalopram may increase the anticoagulant activities of Anistreplase.
ApixabanThe risk or severity of adverse effects can be increased when Citalopram is combined with Apixaban.
ApomorphineApomorphine may increase the QTc-prolonging activities of Citalopram.
AprepitantThe serum concentration of Citalopram can be increased when it is combined with Aprepitant.
ArformoterolArformoterol may increase the QTc-prolonging activities of Citalopram.
AripiprazoleThe risk or severity of adverse effects can be increased when Citalopram is combined with Aripiprazole.
ArmodafinilThe serum concentration of Citalopram can be increased when it is combined with Armodafinil.
Arsenic trioxideCitalopram may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherCitalopram may increase the QTc-prolonging activities of Artemether.
AsenapineCitalopram may increase the QTc-prolonging activities of Asenapine.
AtazanavirAtazanavir may increase the QTc-prolonging activities of Citalopram.
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Citalopram.
AzithromycinAzithromycin may increase the QTc-prolonging activities of Citalopram.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Citalopram.
BedaquilineBedaquiline may increase the QTc-prolonging activities of Citalopram.
BenzquinamideThe risk or severity of adverse effects can be increased when Citalopram is combined with Benzquinamide.
BexaroteneThe serum concentration of Citalopram can be decreased when it is combined with Bexarotene.
BortezomibThe serum concentration of Citalopram can be increased when it is combined with Bortezomib.
BosentanThe serum concentration of Citalopram can be decreased when it is combined with Bosentan.
BosutinibBosutinib may increase the QTc-prolonging activities of Citalopram.
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Citalopram.
BuserelinBuserelin may increase the QTc-prolonging activities of Citalopram.
BuspironeBuspirone may increase the serotonergic activities of Citalopram.
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Citalopram.
CarphenazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Carphenazine.
CeritinibCeritinib may increase the QTc-prolonging activities of Citalopram.
ChloramphenicolThe serum concentration of Citalopram can be increased when it is combined with Chloramphenicol.
ChlormezanoneThe risk or severity of adverse effects can be increased when Citalopram is combined with Chlormezanone.
ChloroquineChloroquine may increase the QTc-prolonging activities of Citalopram.
ChlorpromazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Citalopram is combined with Chlorprothixene.
CimetidineThe metabolism of Citalopram can be decreased when combined with Cimetidine.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Citalopram.
CisaprideCitalopram may increase the QTc-prolonging activities of Cisapride.
Citric AcidCitalopram may increase the anticoagulant activities of Citric Acid.
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Citalopram.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Citalopram.
ClozapineThe risk or severity of adverse effects can be increased when Citalopram is combined with Clozapine.
CollagenaseThe risk or severity of adverse effects can be increased when Citalopram is combined with Collagenase.
ConivaptanThe serum concentration of Citalopram can be increased when it is combined with Conivaptan.
CrizotinibCrizotinib may increase the QTc-prolonging activities of Citalopram.
CyproheptadineThe therapeutic efficacy of Citalopram can be decreased when used in combination with Cyproheptadine.
Dabigatran etexilateCitalopram may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Citalopram can be decreased when it is combined with Dabrafenib.
DalteparinCitalopram may increase the anticoagulant activities of Dalteparin.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Citalopram.
DasatinibDasatinib may increase the QTc-prolonging activities of Citalopram.
DeferasiroxThe serum concentration of Citalopram can be decreased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Citalopram.
DelavirdineThe serum concentration of Citalopram can be increased when it is combined with Delavirdine.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Citalopram is combined with Deoxycholic Acid.
DesfluraneDesflurane may increase the QTc-prolonging activities of Citalopram.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Citalopram.
DesmopressinThe risk or severity of adverse effects can be increased when Citalopram is combined with Desmopressin.
DextromethorphanCitalopram may increase the serotonergic activities of Dextromethorphan.
DicoumarolCitalopram may increase the anticoagulant activities of Dicoumarol.
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Citalopram.
DisopyramideCitalopram may increase the QTc-prolonging activities of Disopyramide.
DofetilideCitalopram may increase the QTc-prolonging activities of Dofetilide.
DolasetronDolasetron may increase the QTc-prolonging activities of Citalopram.
DomperidoneCitalopram may increase the QTc-prolonging activities of Domperidone.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Citalopram.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Citalopram.
DronedaroneCitalopram may increase the QTc-prolonging activities of Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Citalopram is combined with Droperidol.
Edetic AcidCitalopram may increase the anticoagulant activities of Edetic Acid.
EfavirenzThe serum concentration of Citalopram can be increased when it is combined with Efavirenz.
EliglustatCitalopram may increase the QTc-prolonging activities of Eliglustat.
EnoxaparinCitalopram may increase the anticoagulant activities of Enoxaparin.
EribulinEribulin may increase the QTc-prolonging activities of Citalopram.
ErythromycinErythromycin may increase the QTc-prolonging activities of Citalopram.
EscitalopramCitalopram may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Citalopram can be increased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe serum concentration of Citalopram can be increased when it is combined with Esomeprazole.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Citalopram.
Ethyl biscoumacetateCitalopram may increase the anticoagulant activities of Ethyl biscoumacetate.
EtravirineThe serum concentration of Citalopram can be increased when it is combined with Etravirine.
EzogabineEzogabine may increase the QTc-prolonging activities of Citalopram.
FamotidineFamotidine may increase the QTc-prolonging activities of Citalopram.
FelbamateFelbamate may increase the QTc-prolonging activities of Citalopram.
FencamfamineThe risk or severity of adverse effects can be increased when Citalopram is combined with Fencamfamine.
FingolimodFingolimod may increase the QTc-prolonging activities of Citalopram.
FlecainideFlecainide may increase the QTc-prolonging activities of Citalopram.
FluconazoleFluconazole may increase the QTc-prolonging activities of Citalopram.
FluoxetineCitalopram may increase the QTc-prolonging activities of Fluoxetine.
FlupentixolCitalopram may increase the QTc-prolonging activities of Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Fluphenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Citalopram is combined with Fluspirilene.
Fluticasone PropionateFluticasone Propionate may increase the QTc-prolonging activities of Citalopram.
FluvoxamineThe serum concentration of Citalopram can be increased when it is combined with Fluvoxamine.
Fondaparinux sodiumCitalopram may increase the anticoagulant activities of Fondaparinux sodium.
FormoterolFormoterol may increase the QTc-prolonging activities of Citalopram.
FosaprepitantThe serum concentration of Citalopram can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Citalopram.
FosphenytoinFosphenytoin may increase the QTc-prolonging activities of Citalopram.
Fusidic AcidThe serum concentration of Citalopram can be increased when it is combined with Fusidic Acid.
Gadobenic acidGadobenate Dimeglumine may increase the QTc-prolonging activities of Citalopram.
GalantamineGalantamine may increase the QTc-prolonging activities of Citalopram.
GemfibrozilThe serum concentration of Citalopram can be increased when it is combined with Gemfibrozil.
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Citalopram.
GlucosamineGlucosamine may increase the antiplatelet activities of Citalopram.
GoserelinGoserelin may increase the QTc-prolonging activities of Citalopram.
GranisetronGranisetron may increase the QTc-prolonging activities of Citalopram.
HaloperidolThe risk or severity of adverse effects can be increased when Citalopram is combined with Haloperidol.
HeparinCitalopram may increase the anticoagulant activities of Heparin.
HistrelinHistrelin may increase the QTc-prolonging activities of Citalopram.
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Citalopram.
IbandronateIbandronate may increase the QTc-prolonging activities of Citalopram.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Citalopram is combined with Ibritumomab.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Citalopram.
IbutilideCitalopram may increase the QTc-prolonging activities of Ibutilide.
IcosapentCitalopram may increase the antiplatelet activities of Icosapent.
IdelalisibThe serum concentration of Citalopram can be increased when it is combined with Idelalisib.
IloperidoneCitalopram may increase the QTc-prolonging activities of Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Citalopram.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Citalopram.
IndapamideIndapamide may increase the QTc-prolonging activities of Citalopram.
Insulin HumanCitalopram may increase the hypoglycemic activities of Insulin Regular.
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Citalopram.
Ioflupane I 123Citalopram may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Citalopram.
IsoniazidThe serum concentration of Citalopram can be increased when it is combined with Isoniazid.
IsradipineIsradipine may increase the QTc-prolonging activities of Citalopram.
ItraconazoleItraconazole may increase the QTc-prolonging activities of Citalopram.
IvabradineIvabradine may increase the QTc-prolonging activities of Citalopram.
IvacaftorThe serum concentration of Citalopram can be increased when it is combined with Ivacaftor.
KetoconazoleThe serum concentration of Citalopram can be increased when it is combined with Ketoconazole.
L-TryptophanL-Tryptophan may increase the serotonergic activities of Citalopram.
LapatinibLapatinib may increase the QTc-prolonging activities of Citalopram.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Citalopram.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Citalopram.
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Citalopram.
LimaprostLimaprost may increase the antiplatelet activities of Citalopram.
LinezolidLinezolid may increase the serotonergic activities of Citalopram.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Citalopram.
LithiumLithium may increase the serotonergic activities of Citalopram.
LopinavirCitalopram may increase the QTc-prolonging activities of Lopinavir.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Citalopram.
LoxapineThe risk or severity of adverse effects can be increased when Citalopram is combined with Loxapine.
LuliconazoleThe serum concentration of Citalopram can be increased when it is combined with Luliconazole.
LumefantrineCitalopram may increase the QTc-prolonging activities of Lumefantrine.
MaprotilineMaprotiline may increase the QTc-prolonging activities of Citalopram.
MefloquineMefloquine may increase the QTc-prolonging activities of Citalopram.
MesoridazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Mesoridazine.
MethadoneMethadone may increase the QTc-prolonging activities of Citalopram.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Methotrimeprazine.
Methylene blueCitalopram may increase the serotonergic activities of Methylene blue.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Citalopram.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Citalopram.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Citalopram.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Citalopram.
MifepristoneMifepristone may increase the QTc-prolonging activities of Citalopram.
MirabegronMirabegron may increase the QTc-prolonging activities of Citalopram.
MirtazapineMirtazapine may increase the QTc-prolonging activities of Citalopram.
MitotaneThe serum concentration of Citalopram can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Citalopram can be increased when it is combined with Modafinil.
MoexiprilMoexipril may increase the QTc-prolonging activities of Citalopram.
MolindoneThe risk or severity of adverse effects can be increased when Citalopram is combined with Molindone.
MorphineMorphine may increase the serotonergic activities of Citalopram.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Citalopram.
NelfinavirThe metabolism of Citalopram can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Citalopram can be increased when it is combined with Netupitant.
NicardipineThe serum concentration of Citalopram can be increased when it is combined with Nicardipine.
NilotinibCitalopram may increase the QTc-prolonging activities of Nilotinib.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Citalopram.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Citalopram.
ObinutuzumabThe risk or severity of adverse effects can be increased when Citalopram is combined with Obinutuzumab.
OctreotideOctreotide may increase the QTc-prolonging activities of Citalopram.
OfloxacinOfloxacin may increase the QTc-prolonging activities of Citalopram.
OlanzapineThe risk or severity of adverse effects can be increased when Citalopram is combined with Olanzapine.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Citalopram.
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Citalopram.
OmeprazoleThe serum concentration of Citalopram can be increased when it is combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Citalopram is combined with Ondansetron.
OsimertinibOsimertinib may increase the QTc-prolonging activities of Citalopram.
OxytocinOxytocin may increase the QTc-prolonging activities of Citalopram.
PalbociclibThe serum concentration of Citalopram can be increased when it is combined with Palbociclib.
PaliperidoneCitalopram may increase the QTc-prolonging activities of Paliperidone.
PanobinostatPanobinostat may increase the QTc-prolonging activities of Citalopram.
ParoxetineParoxetine may increase the QTc-prolonging activities of Citalopram.
PasireotidePasireotide may increase the QTc-prolonging activities of Citalopram.
PazopanibPazopanib may increase the QTc-prolonging activities of Citalopram.
PentamidinePentamidine may increase the QTc-prolonging activities of Citalopram.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Citalopram.
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Citalopram.
PerflutrenPerflutren may increase the QTc-prolonging activities of Citalopram.
PerphenazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Perphenazine.
PhenelzinePhenelzine may increase the serotonergic activities of Citalopram.
PhenindioneCitalopram may increase the anticoagulant activities of Phenindione.
PhenprocoumonCitalopram may increase the anticoagulant activities of Phenprocoumon.
PhenytoinThe metabolism of Citalopram can be increased when combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Citalopram is combined with Pimozide.
PiperacetazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Piperacetazine.
PosaconazolePosaconazole may increase the QTc-prolonging activities of Citalopram.
PrimaquinePrimaquine may increase the QTc-prolonging activities of Citalopram.
ProcainamideCitalopram may increase the QTc-prolonging activities of Procainamide.
ProchlorperazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Prochlorperazine.
PromazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Promazine.
PromethazinePromethazine may increase the QTc-prolonging activities of Citalopram.
PropafenonePropafenone may increase the QTc-prolonging activities of Citalopram.
PropofolPropofol may increase the QTc-prolonging activities of Citalopram.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Citalopram.
QuetiapineCitalopram may increase the QTc-prolonging activities of Quetiapine.
QuinidineCitalopram may increase the QTc-prolonging activities of Quinidine.
QuinineCitalopram may increase the QTc-prolonging activities of Quinine.
RanolazineRanolazine may increase the QTc-prolonging activities of Citalopram.
RemoxiprideThe risk or severity of adverse effects can be increased when Citalopram is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Citalopram is combined with Reserpine.
ReteplaseCitalopram may increase the anticoagulant activities of Reteplase.
RidogrelCitalopram may increase the anticoagulant activities of Ridogrel.
RifampicinThe serum concentration of Citalopram can be decreased when it is combined with Rifampicin.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Citalopram.
RisperidoneThe risk or severity of adverse effects can be increased when Citalopram is combined with Risperidone.
RitonavirRitonavir may increase the QTc-prolonging activities of Citalopram.
RivaroxabanCitalopram may increase the anticoagulant activities of Rivaroxaban.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Citalopram.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Citalopram.
SaquinavirSaquinavir may increase the QTc-prolonging activities of Citalopram.
SertindoleThe risk or severity of adverse effects can be increased when Citalopram is combined with Sertindole.
SertralineThe serum concentration of Citalopram can be increased when it is combined with Sertraline.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Citalopram.
SiltuximabThe serum concentration of Citalopram can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Citalopram can be increased when it is combined with Simeprevir.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Citalopram.
SorafenibSorafenib may increase the QTc-prolonging activities of Citalopram.
SotalolCitalopram may increase the QTc-prolonging activities of Sotalol.
St. John's WortThe serum concentration of Citalopram can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Citalopram can be increased when it is combined with Stiripentol.
StreptokinaseCitalopram may increase the anticoagulant activities of Streptokinase.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Citalopram.
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Citalopram.
SulodexideCitalopram may increase the anticoagulant activities of Sulodexide.
SulpirideThe risk or severity of adverse effects can be increased when Citalopram is combined with Sulpiride.
SunitinibSunitinib may increase the QTc-prolonging activities of Citalopram.
TacrolimusTacrolimus may increase the QTc-prolonging activities of Citalopram.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Citalopram.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Citalopram.
TelavancinTelavancin may increase the QTc-prolonging activities of Citalopram.
TelithromycinTelithromycin may increase the QTc-prolonging activities of Citalopram.
TenecteplaseCitalopram may increase the anticoagulant activities of Tenecteplase.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Citalopram.
TetrabenazineCitalopram may increase the QTc-prolonging activities of Tetrabenazine.
ThioridazineCitalopram may increase the QTc-prolonging activities of Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Citalopram is combined with Thiothixene.
TiclopidineThe serum concentration of Citalopram can be increased when it is combined with Ticlopidine.
TipranavirTipranavir may increase the antiplatelet activities of Citalopram.
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Citalopram.
TocilizumabThe serum concentration of Citalopram can be decreased when it is combined with Tocilizumab.
TolterodineTolterodine may increase the QTc-prolonging activities of Citalopram.
ToremifeneCitalopram may increase the QTc-prolonging activities of Toremifene.
TositumomabThe risk or severity of adverse effects can be increased when Citalopram is combined with Tositumomab.
TramadolCitalopram may increase the neuroexcitatory activities of Tramadol.
TranylcypromineTranylcypromine may increase the serotonergic activities of Citalopram.
TrazodoneCitalopram may increase the serotonergic activities of Trazodone.
TreprostinilCitalopram may increase the anticoagulant activities of Treprostinil.
TrichlormethiazideCitalopram may increase the activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Triflupromazine.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Citalopram.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Citalopram.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Citalopram.
UrokinaseCitalopram may increase the anticoagulant activities of Urokinase.
VandetanibCitalopram may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Citalopram.
VemurafenibCitalopram may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Citalopram.
VilanterolVilanterol may increase the QTc-prolonging activities of Citalopram.
Vitamin EVitamin E may increase the antiplatelet activities of Citalopram.
VoriconazoleThe serum concentration of Citalopram can be increased when it is combined with Voriconazole.
VorinostatVorinostat may increase the QTc-prolonging activities of Citalopram.
WarfarinCitalopram may increase the anticoagulant activities of Warfarin.
ZiprasidoneCitalopram may increase the QTc-prolonging activities of Ziprasidone.
ZuclopenthixolCitalopram may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Avoid St.John's Wort.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Eriksson E, Engberg G, Bing O, Nissbrandt H: Effects of mCPP on the extracellular concentrations of serotonin and dopamine in rat brain. Neuropsychopharmacology. 1999 Mar;20(3):287-96. [PubMed:10063489 ]
  2. Maines LW, Keck BJ, Smith JE, Lakoski JM: Corticosterone regulation of serotonin transporter and 5-HT1A receptor expression in the aging brain. Synapse. 1999 Apr;32(1):58-66. [PubMed:10188639 ]
  3. Vicentic A, Battaglia G, Carroll FI, Kuhar MJ: Serotonin transporter production and degradation rates: studies with RTI-76. Brain Res. 1999 Sep 11;841(1-2):1-10. [PubMed:10546982 ]
  4. Dugar A, Keck BJ, Maines LW, Miller S, Njai R, Lakoski JM: Compensatory responses in the aging hippocampal serotonergic system following neurodegenerative injury with 5,7-dihydroxytryptamine. Synapse. 2001 Feb;39(2):109-21. [PubMed:11180498 ]
  5. Dutta AK, Fei XS, Beardsley PM, Newman JL, Reith ME: Structure-activity relationship studies of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives and their N-analogues: evaluation of O-and N-analogues and their binding to monoamine transporters. J Med Chem. 2001 Mar 15;44(6):937-48. [PubMed:11300876 ]
  6. Plenge P, Wiborg O: High- and low-affinity binding of S-citalopram to the human serotonin transporter mutated at 20 putatively important amino acid positions. Neurosci Lett. 2005 Aug 5;383(3):203-8. Epub 2005 Apr 25. [PubMed:15955412 ]
  7. Schloss P, Betz H: Heterogeneity of antidepressant binding sites on the recombinant rat serotonin transporter SERT1. Biochemistry. 1995 Oct 3;34(39):12590-5. [PubMed:7548008 ]
  8. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  9. Zhong H, Hansen KB, Boyle NJ, Han K, Muske G, Huang X, Egebjerg J, Sanchez C: An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: kinetic binding studies with the ALI/VFL-SI/TT mutant. Neurosci Lett. 2009 Oct 25;462(3):207-12. doi: 10.1016/j.neulet.2009.07.030. Epub 2009 Jul 16. [PubMed:19616061 ]
  10. Rasmussen TN, Plenge P, Bay T, Egebjerg J, Gether U: A single nucleotide polymorphism in the human serotonin transporter introduces a new site for N-linked glycosylation. Neuropharmacology. 2009 Sep;57(3):287-94. doi: 10.1016/j.neuropharm.2009.05.009. Epub 2009 Jun 3. [PubMed:19500602 ]
  11. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Brosen K, Naranjo CA: Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol. 2001 Aug;11(4):275-83. [PubMed:11532381 ]
  2. Rasmussen BB, Brosen K: Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000 Apr;22(2):143-54. [PubMed:10774624 ]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  4. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53. [PubMed:9890159 ]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Brosen K, Naranjo CA: Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol. 2001 Aug;11(4):275-83. [PubMed:11532381 ]
  2. Rasmussen BB, Brosen K: Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000 Apr;22(2):143-54. [PubMed:10774624 ]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  4. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53. [PubMed:9890159 ]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204. [PubMed:12649369 ]
  2. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, Dose T, Ebinger M, Rosenhagen M, Kohli M, Kloiber S, Salyakina D, Bettecken T, Specht M, Putz B, Binder EB, Muller-Myhsok B, Holsboer F: Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008 Jan 24;57(2):203-9. doi: 10.1016/j.neuron.2007.11.017. [PubMed:18215618 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on April 15, 2016 11:25